Global recruitment of Principle Medical Scientist/Clinical Research Director

1. Job Summary

Supporting SINOVAC’s robust pipeline development, the clinical research team works closely with the R&D scientists and is dedicated to scientific design and promoting the clinical trials of drugs. As the Principle Medical Scientist, you will provide strategic perspectives on clinical decision-making regarding unmet medical needs and clinical data, further clinical development plans, and ensure efficient and compliant clinical trials. You will also bridge cooperation between SINOVAC, experts, and institutions, promote knowledge exchange, and ensure smooth R&D processes through collaboration with multiple institutions. With your team also acting as an industry insider and strategic investment think tank, you will provide forward-looking advice to ensure the scientific credibility and maneuverability of investment decisions. Your professional leadership and outstanding contributions will strive to produce results for SINOVAC’s drug R&D.

2. Roles and Responsibilities

1. Develop clinical drug development strategies and lead the implementation of R&D plans.
2. Responsible for reviewing and approving technical materials such as protocols, clinical study reports, and registered clinical materials for drug projects.
3. Responsible for establishing collaborative relationships with domestic and foreign research institutions and experts in relevant fields.
4. Responsible for interacting with regulatory agencies, principle investigators, technical partners, CRO, and other clinical-related institutions
5. Collaborate with the R&D department to provide medical support on product design, market positioning, and preclinical research.
6. Responsible for the research and analysis of industry medical projects, accurately analyzing industry development, providing unique insights into the latest scientific and technological advancements.
7. Assist SINOVAC in strategic investment in pharmaceutical projects. Provide judgments on medical value, clinical needs, and commercialization prospects.

3. Qualification and Requirements

1. Ph.D in clinical medicine, 35-50 years old, with priority given to top Chinese and international universities.
2. At least 10 years of experience in medical work for drug research and development, with preference given to candidates who have experience working in both multinational pharmaceutical and innovative biotech companies.
3. Experience in independently or jointly leading early drug development process, clinical research, and registration for market launch.
4. Familiar with experts and academic resources in at least one or more specialized disease areas, with priority given to therapeutic areas such as oncology, metabolism, and respiratory diseases.
5. Capable of independently searching for English literature, participating in international academic conferences, and engaging in academic exchange with international peers. Fluency in both written and spoken English is required.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a Chinese biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines and antibodies. SINOVAC also produces other preventive and therapeutic products that protect against human infectious diseases.

SINOVAC is dedicated to addressing major challenges in disease prevention and treatment through cutting-edge technology. We focus on unmet medical needs regarding infectious disease and other significant therapeutic areas. All our work integrates cutting-edge research and major findings from across the world, concentrating strengths to develop first-in-class biopharmaceuticals such as vaccines, antibodies, and fusion proteins, ensuring high-quality products reach the market swiftly. Our high R&D standards are backed by innovation-driven platforms such as the United Research Institute of SINOVAC (URIS) for drug discovery and our product-oriented CMC platform. We also run clinical demand support platforms such as our Analysis Center and Animal Center for Drug Evaluation. Our world-class facilities mean we have a mature system for developing preventive and therapeutic products, with multiple types of technologies including our own core technologies. Our multidisciplinary research team, covering fields such as pharmacy, biology, medicine, and chemistry, are at the forefront of global research and innovation.

Going forward, SINOVAC will promote both the research and industrialization of biopharmaceuticals. While continuing to develop its vaccine industry, we will also expand our markets in therapeutic monoclonal antibodies, gene therapy, and cell therapy. Through independent R&D, collaboration, and external investment, we will accelerate the industrialization of high-quality biopharmaceuticals to fulfil global disease prevention and control, improving global health and well-being.

Since being founded in 2001, our mission has been to “supply vaccines to eliminate human diseases”. SINOVAC has developed a comprehensive portfolio including vaccines against common infectious diseases like hepatitis virus, seasonal influenza, pneumococcal disease, poliomyelitis, varicella, and mumps, as well as emerging ones, such as COVID-19, enterovirus71 (EV71) related Hand-Foot-Mouth disease (HFMD), H5N1 influenza (avian flu), H1N1 influenza (swine flu) and SARS.

Thanks to its comprehensive quality management, SINOVAC has four vaccines approved by the World Health Organization (WHO). Its hepatitis A vaccine Healive®, Sabin-strain inactivated poliomyelitis vaccine (sIPV), and varicella vaccine were granted WHO prequalification (“PQ”); and its COVID-19 vaccine CoronaVac® was validated by the WHO under the Emergency Use Listing (“EUL”) Procedure.